List of Diagnostics Companies in Australia - 17

The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.

Atomo Diagnostics is a medical device manufacturer headquartered in Sydney, Australia with offices in South Africa and the United Kingdom. Atomo Diagnostics was established to capitalise on a core belief that healthcare products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants. In 2013, Atomo introduced AtomoRapid, a range of safe, simple professional use tests that deliver fast and accurate results in both clinical and community settings. In 2014, AtomoRapid HIV won Best in Show at the Medical Device Excellence Awards (MDEA) and Atomo was named Australian Emerging Company of the Year for 2014 by Johnson & Johnson Innovation. Atomo is committed to increasing the early detection and ongoing treatment of infectious and chronic diseases by making testing safer, more accurate and more accessible. Visit our website, www.atomodiagnostics.com, for more information on our company and products.

AusDiagnostics Pty Ltd is a leading international company that designs, manufactures and markets a comprehensive suite of multiplexing molecular diagnostic assays and reagents. Founded in August 2006, AusDiagnostics also supports robotic instruments for human diagnostics, animal diagnostics and applied testing. In the past five years, the company has expanded its reach to global customers through offices in New Zealand, the United Kingdom and the United States. In 2018, AusDiagnostics opened a manufacturing facility in the United Kingdom to support the supply of products to its growing network of distribution partners in more than 25 countries. AusDiagnostics continues to develop new technology, and conduct scientific research into innovative diagnostic methodologies for customers around the world.

Avania brings knowledgeable experts together to form a unique CRO that advances the research of medical devices, novel technology, and combination products across a wide range of therapeutic specialties. Our motivated team takes you from feasibility all the way through post-market trials. Our experts in data management and analytics, clinical trial design & execution, strategic consulting, regulatory, reimbursement, and more will provide you with customized, scalable solutions that optimize efficiencies and streamline the advancement of your medical technology. Your product is important, and your company deserves the team that has what it takes. It takes knowledge. It takes passion. It takes commitment. It takes Avania.

BCAL Diagnostics is an Australian-owned, ASX listed, biotechnology company. Since its establishment in 2010, BCAL Diagnostics has been striving to help identify health issues in women that is safe, accessible and cost effective.

Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) and traded on the OTC markets in the U.S.A. with business presence in Australia, China, Japan and the USA. It currently has four core businesses – cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences, and environmental science industries.

Cyclomedica is a global leader in nuclear medicine and molecular imaging, focusing on innovative diagnostic solutions for respiratory diseases. As a subsidiary of Cyclopharm Limited, the company is known for its flagship product, Technegas®, a lung imaging agent that enables high-resolution ventilation scans for conditions such as pulmonary embolism and COPD. Founded on advancements in radiopharmaceutical technology, Cyclomedica aims to improve patient outcomes through early intervention and enhanced care protocols. The company has a strong global presence, having expanded into various markets since its inception. It offers additional products like Pertechnegas, a specialized diagnostic application, and Galligas, a PET imaging variant. Cyclomedica also employs 3D SPECT imaging to enhance diagnostic accuracy in nuclear pulmonology. With ongoing research initiatives and a strategic focus on U.S. market expansion, Cyclomedica continues to advance its mission of elevating standards in respiratory disease management.

Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Ellume is an Australian based Health Technology company that develops and manufactures connected real-time diagnostics for doctors and consumers. We achieve this by combining next-generation quantum dot diagnostics with connected care technologies. Our products are distinguished by their simplicity of design, ease of use, rapid time to result and connectivity. To learn more about Ellume, visit our website at www.ellumehealth.com.

Genetype - Unlocking personalised preventative health Genetic Technologies (ASX: GTG, NASDAQ Global Market: GENE) is a leader in the development and commercialisation of genetic risk assessment technology. Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone. We’re transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information, they need to manage their health according to their own risk.

LBT Innovations is a medical technology company that utilizes artificial intelligence to deliver automation in healthcare through a patent-protected machine learning and intelligent imaging platform.

Microba Life Sciences is a precision microbiome company driven to advance health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Proteomics International Laboratories Limited (ASX:PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease. Proteomics International is now implementing a stepped rollout of PromarkerD, its flagship diagnostic test for diabetic kidney disease, globally. Successful commercialisation of this diagnostic test is expected to bolster Proteomics' revenue base. PromarkerD licensing fees and royalty payments will rise as the test is adopted by more physicians and licensed into new geographic regions. The Company is, at the same time, continuing to research potential diagnostic tests for other diseases, including endometriosis, asthma, COPD, oesophageal cancer, Diabetic retinopathy and oxidative stress. Proteomics' Analytical Services unit provides fee-for-service revenue, which helps financially support the Company's commercialisation and research activities. To learn more please visit: www.proteomics.com.au/

Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic applications. The company is focused on innovating the way we see and treat cancer, with a particular emphasis on HER-2 cancers. Radiopharm Theranostics has a strong team of executives and board members, and is actively engaged in investor relations and corporate governance. The company has also launched a joint venture with MD Anderson to focus on novel radiopharmaceuticals.

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Tessara Therapeutics Pty Ltd is a regenerative medicine company developing RealBrain® technology to break therapeutic barriers in the biopharmaceutical industry. RealBrain® technology is based on human mimetic 3D neural micro-tissues designed to have high physiological relevance, manufactured at industrial scale for unprecedented reproducibility. Priority applications include a high-throughput drug screening platform that includes a range of models of healthy and diseased brain tissue, and a regenerative medicine platform to develop next generation safe and efficacious tissue therapies for significant unmet neurological medical needs.

Universal Biosensors Inc (UBI) is a global biosensor company and a world leader in electrochemical cell technology. UBI's ambition is to utilize its patented biosensor technology to develop a diverse range of biosensor test strips used in our hand-held portable analyzers; for cost effective, effortless, and accurate detection of analytes of interest, within many industries including human health, animal health, environmental, and agriculture. UBI is a USA Delaware company listed on the Australian Securities Exchange (ASX:UBI) and operates from its head office, manufacturing facility, and research laboratory in Melbourne, Victoria, Australia. In 2021, UBI successfully launched its unique handheld wine analyzer called Sentia™ with an initial test to measure free SO2 , and subsequently in 2022, tests for monitoring malic acid and glucose throughout the wine production process (more tests in the pipeline are due for release in late 2022). In 2022, UBI launched Xprecia Prime™ in the EU and UK, the next-generation blood coagulation analyzer which replaces Xprecia Stride™. Xprecia Prime™ is due for launch in the US in 2023. UBI is due to launch Petrackr™ in late 2022/early 2023, a veterinary blood glucometer to monitor diabetes in cats and dogs. These products will complement UBI's existing Canadian blood testing laboratory Hemostasis Reference Lab (HRL).